fortum stungulyfsstofn lausn 1 g - leitarniðurstöður

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fortum stungulyfsstofn, lausn 1 g

sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fortum stungulyfs-/innrennslisstofn, lausn 2 g

sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g

Evrópusambandið - íslenska - EMA (European Medicines Agency)

padcev

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Æxlishemjandi lyf - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

xeomin stungulyfsstofn, lausn 100 ein.

merz pharmaceuticals gmbh - botulinum toxin type a - stungulyfsstofn, lausn - 100 ein.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

bortezomib actavis stungulyfsstofn, lausn 3,5 mg

actavis group ptc ehf. - bortezomibum inn - stungulyfsstofn, lausn - 3,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sendoxan stungulyfsstofn, lausn 1 g

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sendoxan stungulyfsstofn, lausn 500 mg

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 500 mg